<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Thase, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">K Ryan Connolly, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3834084692"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> is a racemic mixture of two enantiomers, S-ketamine (<a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a>) and R-ketamine [<a href="#rid1">1</a>]. Ketamine is a standard anesthetic drug that is also administered for analgesia and sedation [<a href="#rid2">2,3</a>]. In addition, ketamine and esketamine can rapidly and transiently alleviate treatment-resistant unipolar major depression, including suicidal ideation [<a href="#rid4">4,5</a>]. Although use of ketamine to treat depression has increased [<a href="#rid6">6,7</a>], we suggest that clinicians prescribe ketamine or esketamine cautiously for this indication, only after exhausting other recommended nonelectroconvulsive therapy treatments for resistant depression. This approach is consistent with clinical guidance from the American Psychiatric Association and other experts [<a href="#rid8">8,9</a>].</p><p>This topic discusses treatment of resistant depression with <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> and <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a>, including their administration, efficacy, and adverse effects. Separate topics discuss the general principles of treating resistant depression; choosing a specific treatment for resistant depression; and the epidemiology, risk factors, assessment, and prognosis of treatment-resistant depression, as well as using ketamine to induce general anesthesia.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/119986.html" rel="external">"Unipolar depression in adults: General principles of treating resistant depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/87498.html" rel="external">"Unipolar treatment-resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Ketamine'</a>.)</p><p></p><p class="headingAnchor" id="H2356153840"><span class="h1">CHEMICAL STRUCTURE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> is a racemic mixture of two enantiomers that are mirror images of each other and thus not identical in that they cannot be superimposed upon each other (similar to one’s hands) [<a href="#rid1">1</a>]. One of the enantiomers, S-ketamine (<a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a>), binds more potently to the N-methyl-D-aspartate receptor than the other enantiomer, R-ketamine. (See <a class="local">'Mechanism of action'</a> below.)</p><p class="headingAnchor" id="H1163049110"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>The mechanism of action for the rapid antidepressant effects of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> and <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> is not known [<a href="#rid3">3</a>]. However, several studies indicate that ketamine has an affinity for multiple receptors [<a href="#rid2">2,10</a>], which has given rise to the hypothesis that the drug binds to, or secondarily affects, different types of receptors that initiate cascading effects acting in concert [<a href="#rid10">10</a>]. The receptors that may be involved include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioid receptor</strong> – <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> is an opioid receptor agonist, which may explain its efficacy for acute pain [<a href="#rid2">2,6,11,12</a>]. Evidence that indicates activation of opioid receptors is involved in ketamine’s antidepressant effects includes a randomized crossover trial that compared <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> 50 mg with placebo, which were given prior to ketamine 0.5 mg/kg infused over 40 minutes [<a href="#rid13">13</a>]. Naltrexone is an opioid receptor antagonist. Patients with treatment-resistant depression were randomly assigned to the order in which they received each study treatment (naltrexone-ketamine or placebo-ketamine), each study treatment was administered once separated by at least 14 days, and patients were depressed at the time of receiving each study treatment. Among the 12 patients who completed both ketamine infusions, improvement was far less with naltrexone-ketamine than placebo-ketamine on postinfusion days 1 and 3. Use of ketamine for acute pain is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/133187.html" rel="external">"Nonopioid pharmacotherapy for acute pain in adults", section on 'Ketamine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>N-methyl-D-aspartate (NMDA) receptor</strong> – Glutamate is the primary excitatory neurotransmitter in the brain and binds to several types of receptors, including the NMDA receptor [<a href="#rid14">14</a>]. Although it is established that <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> is an NMDA receptor antagonist, it is not clear whether NMDA antagonism mediates the drug’s antidepressant effects [<a href="#rid15">15</a>]. Evidence that suggests NMDA antagonism may be involved includes randomized trials that found intravenous racemic ketamine 0.2 mg/kg was not effective, whereas 0.2 mg/kg of the stereoisomer <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a>, which is more potent at NMDA receptors [<a href="#rid2">2,16</a>], was effective [<a href="#rid16">16,17</a>] . However, other NMDA antagonists such as <a class="drug drug_general" data-topicid="10131" href="/z/d/drug information/10131.html" rel="external">memantine</a> are not effective for treatment-resistant depression [<a href="#rid4">4,10</a>]. (See  <a class="medical medical_review" href="/z/d/html/90155.html" rel="external">"Unipolar depression in adults: Investigational and nonstandard treatment", section on 'Medications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor</strong> – The AMPA receptor is also involved in glutamate neurotransmission, and <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>’s antidepressant effects may be due at least partially to activation of the AMPA receptor by the ketamine metabolite (2R, 6R)-hydroxynorketamine. In a preclinical study, mice received ketamine, the metabolite (2R, 6R)-hydroxynorketamine, or the metabolite (2S, 6S)-hydroxynorketamine [<a href="#rid18">18</a>]. Antidepressant-like effects were assessed using the forced swim test, learned helplessness test, and novelty suppressed feeding test. Ketamine and (2R, 6R)-hydroxynorketamine each generated antidepressant responses that did not occur with (2S, 6S)-hydroxynorketamine. In addition, the investigators found that (2R, 6R)-hydroxynorketamine activates AMPA receptors, but does not bind to or inhibit (antagonize) the NMDA receptor, and that blocking the AMPA receptors blocked the antidepressant effects of the metabolite.</p><p></p><p>Other studies have examined <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>’s mechanism of action at the level of brain structures. As an example, functional neuroimaging studies in patients with treatment-resistant depression suggest that ketamine may improve depression by activating of the anterior cingulate cortex [<a href="#rid19">19</a>] and by increasing connectivity between the insula and default mode network.</p><p>In addition, a rodent study suggested that neuronal vascular endothelial growth factor signaling in the prefrontal cortex may mediate the rapid antidepressant actions of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> [<a href="#rid20">20</a>]. Another preclinical study administered ketamine to rodents with depression-like behaviors (eg, immobility in the forced swim test) induced genetically or by exposure to chronic stress, and found that neuronal activity in the habenula diminished to the level observed in control rodents, and that the depressed-like rodents behaved like the control rodents [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3446412333"><span class="h1">KETAMINE</span></p><p class="headingAnchor" id="H777292545"><span class="h2">Administration</span></p><p class="headingAnchor" id="H643234019"><span class="h3">Setting</span><span class="headingEndMark"> — </span>Randomized trials of intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for treatment-resistant depression have typically occurred in academic hospital settings in which psychiatrists collaborated with anesthesiologists [<a href="#rid22">22-24</a>]. However, ketamine infusions are becoming increasingly available at freestanding outpatient clinics, in which treatment is dispensed by physicians such as often anesthesiologists, who often have limited to no experience treating depression [<a href="#rid6">6</a>]. In addition, outpatients have been treated with oral ketamine ingested at home [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3610145126"><span class="h3">Route (formulation)</span><span class="headingEndMark"> — </span>The optimal method of administering <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for treatment-resistant depression has not been established [<a href="#rid26">26</a>]. Although most studies have given ketamine intravenously, it can also be administered with intramuscular, intranasal, oral, subcutaneous, and sublingual formulations [<a href="#rid2">2,12,25,27-29</a>]. The route of administration affects patient comfort and convenience, as well as bioavailability, serum concentrations, and duration of effect [<a href="#rid26">26,29</a>]. As an example, oral ketamine is more convenient than other routes, but tastes bad and its bioavailability is relatively low due to first pass hepatic metabolism [<a href="#rid29">29</a>]. Intranasal delivery can be problematic because of nasal cavity conditions that impede administration or absorption (eg, mucosal inflammation or deviated septum) and patient difficulty with self-administration [<a href="#rid30">30-32</a>].</p><p>Evidence comparing different routes of administration includes one open-label trial that randomly assigned patients (n = 27) with new onset or treatment-resistant major depression to a single dose of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> given intravenously 0.5 mg/kg, intramuscularly 0.5 mg/kg, or intramuscularly 0.25 mg/kg; response was comparable across the three groups [<a href="#rid33">33</a>]. However, interpreting the results is difficult due to the small and heterogeneous sample, lack of a placebo control, and lack of blinding.</p><p class="headingAnchor" id="H2638438754"><span class="h3">Dose</span><span class="headingEndMark"> — </span>The dose of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for treatment-resistant depression varies depending upon the route and frequency of administration [<a href="#rid26">26,29</a>]. For any particular route of administration, no one dose has been established among the different doses tested.</p><p class="headingAnchor" id="H3890273515"><span class="h4">Intravenous</span><span class="headingEndMark"> — </span>The optimal dose of intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for treatment-resistant depression is not established. Nevertheless, small randomized trials that compared different doses of ketamine suggest that generally, the preferred dose may be 0.5 mg/kg of body weight:</p><p class="bulletIndent1"><span class="glyph">●</span>A one-month trial enrolled 99 patients with treatment-resistant unipolar major depression who were currently treated with antidepressant drugs, and randomly assigned them to add-on <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> or four different doses of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> [<a href="#rid34">34</a>]. Study drugs were administered as a single intravenous infusion over 40 minutes. Ketamine 0.5 mg/kg and 1 mg/kg were each superior to midazolam 0.045 mg at day 1, whereas ketamine 0.1 mg/kg and 0.2 mg/kg were not. The efficacy of the two higher doses was comparable, but dissociation and elevated blood pressure during infusion each appeared to be worse with ketamine 1 mg/kg than 0.5 mg/kg, suggesting a dose response effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another one-month trial randomly assigned patients (n = 71) to a single dose of adjunctive <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> 0.5 mg/kg, ketamine 0.2 mg/kg, or placebo; study drugs were infused over 40 minutes [<a href="#rid16">16</a>]. Improvement was greater with the 0.5 mg/kg dose than placebo, whereas improvement was comparable for the 0.2 mg/kg dose and placebo. However, improvement with the 0.5 mg/kg and 0.2 mg/kg doses was also comparable.</p><p></p><p>In addition, short-term randomized trials, which compared <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> with placebo or active controls and established the efficacy of ketamine, typically used 0.5 mg/kg, infused over 40 minutes. (See <a class="local">'Short-term efficacy'</a> below.)</p><p>However, dose adjustments may be appropriate for specific patients [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A dose of 0.75 or 1 mg/kg may be suitable for patients not responsive to 0.5 mg/kg [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are obese, as indicated by a body mass index ≥30 kg/m<sup>2</sup> (<a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">calculator 1</a>), it may be safer to calculate the dose according to ideal body weight and not the actual weight. Limited evidence supporting this approach includes a pooled analysis of three randomized trials, which included 97 patients who received a total of 205 infusions; transient blood pressure &gt;180/100 mmHg or pulse &gt;110 beats/minute occurred in 30 percent of patients [<a href="#rid35">35</a>]. These changes were more likely to occur in obese patients and patients who received larger average doses of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> (46 versus 42 mg).</p><p></p><p>Although the standard rate of infusion appears to be 40 minutes [<a href="#rid8">8</a>], across different studies the rate has varied from 2 to 100 minutes [<a href="#rid29">29</a>]. Relatively slower rates may mitigate sedation and other adverse effects.</p><p>The expected peak serum concentration of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> 0.5 mg/kg over 40 minutes ranges from 70 to 200 ng/mL [<a href="#rid8">8</a>].</p><p>The intravenous dose used for depression is typically less than the dose used for inducing general anesthesia. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Dosing'</a>.)</p><p class="headingAnchor" id="H3765785970"><span class="h4">Other formulations</span><span class="headingEndMark"> — </span>The dose of oral and intranasal <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral</strong> – The optimal dose of oral <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for treatment-resistant depression is not established. In one small randomized trial that compared ketamine with placebo, the dose of ketamine was 1 mg/kg of body weight [<a href="#rid25">25</a>]. (See <a class="local">'Other formulations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intranasal</strong> – The preferred dose of intranasal <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for treatment-resistant depression is not established. In one small randomized trial that compared ketamine with placebo, the dose of ketamine was 50 mg [<a href="#rid28">28</a>]. (See <a class="local">'Other formulations'</a> below.)</p><p></p><p class="headingAnchor" id="H2624334257"><span class="h3">Frequency</span><span class="headingEndMark"> — </span>It is not clear how frequently <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> should be administered [<a href="#rid26">26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous</strong> – Although the number of times that intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> 0.5 mg/kg is administered per week for treatment-resistant depression is not established, the evidence suggests that the drug should be given once or twice per week. In most randomized trials, the drug was given only one time and the benefit appeared to diminish over the following week. In one trial that infused ketamine twice weekly or thrice weekly for up to six weeks, improvement of depression with the two dosing frequencies was comparable [<a href="#rid36">36</a>]. (See <a class="local">'Repeated intravenous infusions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral</strong> – The number of times that oral <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> is administered per week for treatment-resistant depression is not established (nor is the dose established). One randomized trial administered ketamine 1 mg/kg thrice weekly because of the low and variable bioavailability of oral ketamine [<a href="#rid25">25</a>]. (See <a class="local">'Other formulations'</a> below.)</p><p></p><p class="headingAnchor" id="H2074159890"><span class="h2">Concurrent treatment</span><span class="headingEndMark"> — </span>The patient's current medications, including prescription, over-the-counter, and complementary or alternative drugs should be reviewed prior to use of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>. The psychiatrist, anesthesiologist, or general medical consultant should decide which to continue and which to taper and discontinue.</p><p>It appears that <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> can be used concurrently with most standard antidepressants without reducing efficacy or increasing side effects [<a href="#rid37">37</a>]. Across randomized trials, ketamine has been administered either as monotherapy or as add-on therapy to antidepressants and antipsychotics [<a href="#rid4">4,16,25,34,36,38-40</a>]. However, low quality studies report that concomitant benzodiazepines may interfere with response to ketamine [<a href="#rid41">41,42</a>], and one randomized trial withheld benzodiazepines 24 hours prior to infusing ketamine [<a href="#rid40">40</a>].</p><p><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> is metabolized primarily by hepatic cytochrome P450 2B6 and 3A4 [<a href="#rid37">37</a>]. Concomitant drugs that induce these enzymes may decrease exposure to ketamine and drugs that inhibit these enzymes may increase exposure; these effects may necessitate adjusting ketamine doses. Specific interactions of ketamine with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p>During short-term treatment with <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, ongoing administration of prestudy antidepressants may help transition patients from ketamine to continuation and maintenance treatment [<a href="#rid43">43</a>]. In addition, concurrent treatment with psychotherapy, such as cognitive-behavioral therapy, may also help the transition [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H1117265132"><span class="h2">Short-term efficacy</span><span class="headingEndMark"> — </span>For unipolar major depression, the efficacy of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> and <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> appear to be comparable [<a href="#rid1">1</a>]. However, no head-to-head trials comparing the two drugs have been published.</p><p>Randomized trials have demonstrated that intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> can rapidly improve treatment-resistant depression, including symptoms of suicidal ideation. However, most trials administered only a single infusion, and the benefit diminished within two weeks. It is not known how efficacy is influenced by serum concentrations and the interplay of different factors related to administration [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H652881002"><span class="h3">Single intravenous infusion</span><span class="headingEndMark"> — </span>Multiple randomized trials demonstrate that for treatment-resistant depression, a single infusion of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> produces a rapid and robust response (eg, within 40 to 120 minutes) in at least 50 percent of patients [<a href="#rid45">45-49</a>]. However, the effect dissipates by day 10 to 14. As an example:</p><p class="bulletIndent1"><span class="glyph">●</span>One pooled analysis of seven trials compared <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> with placebo (<a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) or active medication in 172 patients with unipolar or bipolar major depression [<a href="#rid4">4</a>]. A single dose of ketamine (0.5 mg/kg) or the control was administered intravenously (six trials) or intranasally (one trial); most patients received no concomitant therapy. Response (reduction of baseline symptoms ≥50 percent) at multiple posttreatment time points occurred in more patients who received ketamine than the control condition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two hours – 51 versus 2 percent of patients</p><p class="bulletIndent2"><span class="glyph">•</span>One day – 53 versus 7 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Seven days – 31 versus 7 percent</p><p></p><p class="bulletIndent1">By day 14, response was present in only 11 percent of the patients who received <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of nine trials compared a single infusion of intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> (0.5 mg/kg infused over 40 minutes) with a control condition (typically placebo) in patients with unipolar depression (n = 208) or bipolar depression (n = 26); study drugs were typically administered as add-on therapy [<a href="#rid38">38</a>]. Response was more likely to occur in patients who received ketamine than controls, starting at 40 minutes and persisting at multiple subsequent time points; at day 7, response was three times more likely with ketamine (relative risk 3, 95% CI 2-7).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent randomized trial compared a single dose of intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> 0.5 mg/kg infused over 40 minutes with placebo in patients who remained depressed despite treatment with at least three successive antidepressants (n = 48) [<a href="#rid16">16</a>]. During the period of one to four days after infusion, response (reduction of baseline depression ≥50 percent) occurred in more patients who received ketamine than placebo (46 versus 13 percent).</p><p></p><p>There are no well-established clinical predictors or biomarkers of acute response to a single infusion of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> [<a href="#rid50">50</a>]. However, response may be more likely to occur in patients who are more severely (intensely) depressed at baseline [<a href="#rid16">16</a>]. In addition, greater dissociation during infusion [<a href="#rid51">51</a>], fewer residual depressive symptoms at day 1 [<a href="#rid51">51</a>], and a positive family history of alcohol use disorder may be associated with antidepressant efficacy [<a href="#rid51">51,52</a>].</p><p>Augmentation with <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> may accelerate response to antidepressant treatment, which often takes 6 to 12 weeks [<a href="#rid53">53</a>]. A four-week randomized trial compared a single infusion of add-on ketamine (0.5 mg/kg) with placebo on day 1 of newly initiated treatment with <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a> 10 mg/day [<a href="#rid54">54</a>]. The sample consisted of 27 patients with unipolar major depression, approximately half of whom were classified as treatment resistant. Study drugs were administered after a two-week washout of prior pharmacotherapy. Response occurred in more patients treated with adjunctive ketamine than placebo (92 versus 57 percent), and the mean time to response was shorter with ketamine plus escitalopram than placebo plus escitalopram (6 versus 27 days). In addition, more than half of the patients responded within two hours of receiving intravenous ketamine, compared with none of the patients who received placebo. None of the patients discontinued treatment due to adverse effects.</p><p>In addition, a prospective observational study found that a single infusion <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> led to a moderately large reduction of depressive symptoms in patients (n = 17) who had previously not responded to electroconvulsive therapy (ECT) [<a href="#rid55">55</a>]. However, the American Psychiatric Association Council of Research Task Force on Novel Biomarkers and Treatments concluded that ketamine is not an alternative to ECT, because following a successful course of treatment with ketamine or ECT, relapse is nearly two times greater with ketamine [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3777028219"><span class="h3">Repeated intravenous infusions</span><span class="headingEndMark"> — </span>Patients not responsive to a single infusion of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> may improve with subsequent infusions, and improvement following a single infusion can be sustained by subsequent infusions [<a href="#rid6">6,29,56</a>]. As an example, a four-week trial randomly assigned patients with treatment-resistant depression (n = 67) to one of four treatments: ketamine two times per week, placebo two times per week, ketamine three times per week, or placebo three times per week [<a href="#rid36">36</a>]. The dose of ketamine was 0.5 mg/kg, and all study drugs were infused intravenously over 40 minutes; current antidepressant drugs were continued. Response (reduction of baseline symptoms ≥50 percent) at day 15 occurred in more patients who received twice weekly ketamine than placebo (69 versus 15 percent) and more often with thrice weekly ketamine than placebo (54 versus 6 percent of patients). The effect size for the two frequencies of ketamine at day 15 was comparable, and the benefit of ketamine persisted throughout the four-week study period.</p><p>In addition, one randomized trial (n = 18) suggests that onset of antidepressant effect may perhaps be faster with repeated infusions of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, compared with repeated treatments with electroconvulsive therapy [<a href="#rid57">57</a>]. A retrospective study found that repeated ketamine infusions may help patients who do not respond to ECT [<a href="#rid58">58</a>]. The benefit of repeated intravenous infusions for inducing general anesthesia in patients receiving electroconvulsive therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1711.html" rel="external">"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)", section on 'Ketamine plus ECT'</a>.)</p><p>Repeated infusions of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> may provide a relatively large, short-term effect compared with other treatments. A network meta-analysis of 31 randomized trials compared the efficacy of different medications, ECT, and repetitive transcranial magnetic stimulation in treatment-resistant depression (sample size not reported); the study used results from direct comparisons between the treatments in head-to-head trials, as well as indirectly comparing treatments through their relative effect with a common comparator (typically placebo) [<a href="#rid59">59</a>]. The largest improvement at two weeks after onset of treatment occurred with ketamine.</p><p class="headingAnchor" id="H2839177373"><span class="h3">Other formulations</span><span class="headingEndMark"> — </span>The efficacy of intranasal and oral <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single intranasal dose</strong> – Short-term improvement of treatment-resistant depression can be achieved with one dose of intranasal <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>. A randomized crossover trial compared a single dose of add-on ketamine (50 mg) with placebo (<a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) in 18 patients [<a href="#rid28">28</a>]. Patients were randomly assigned to the order in which they received each study drug (ketamine-saline or saline-ketamine). In addition, patients received each study treatment separated by at least seven days and were depressed at the time of receiving each study drug. Improvement was greater 40 minutes after administration of ketamine than placebo, and response at 24 hours occurred more often with ketamine than placebo (44 [8/18] versus 6 [1/18] percent of patients). In addition, adverse effects were mild and transient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeated intranasal doses</strong> – A four-week, randomized trial initially planned to compare intranasal <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> (100 mg) with <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> (4.5 mg) in 10 patients with treatment-resistant depression [<a href="#rid30">30</a>]. However, the study was terminated early after five patients were enrolled because of poor tolerability, including elevated blood pressure, motor incoordination, and psychotomimetic effects. Absorption varied among patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeated oral doses</strong> – For treatment-resistant depression, repeated administration of oral <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> can provide short-term improvement. A small, three-week randomized trial compared add-on oral ketamine 1 mg/kg with placebo in patients receiving usual care (n = 40) [<a href="#rid25">25</a>]. Most of the patients had melancholic features and comorbid psychopathology. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received active drug than placebo (32 versus 6 percent). The number needed to treat was approximately four, meaning that for every four patients treated with ketamine and every four treated with placebo, one additional response occurred with ketamine. Follow-up assessments one week after treatment found that the benefit of ketamine persisted. In addition, adverse effects were mild and transient.</p><p></p><p class="headingAnchor" id="H963778187"><span class="h2">Longer-term efficacy</span><span class="headingEndMark"> — </span>The benefits and safety of longer-term <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> treatment are not known, due to the relatively short duration of treatment in high quality studies and the lack of follow-up [<a href="#rid8">8,60</a>]. Only sparse, low quality data are available for continuation and maintenance treatment in patients who respond to acute treatment with ketamine. A prospective observational study of three patients found variable responses during a 12-month course of treatment that included 16 to 34 total infusions 0.5 mg/kg per patient [<a href="#rid61">61</a>]. A second prospective observational study included 14 patients who received 12 to 45 continuation/maintenance intravenous treatments over for 14 to 126 weeks; during two years of follow-up, relapse occurred in all but three patients [<a href="#rid62">62</a>].</p><p>Concerns have been raised that tolerance or tachyphylaxis can occur, such that the antidepressant efficacy of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> declines over time with repeated use; this may lead to progressively larger doses and increased frequency of administration, and eventually to ketamine dependence [<a href="#rid9">9,63</a>]. The concerns include worries about causing a new drug epidemic [<a href="#rid9">9,64</a>]. (See <a class="local">'Longer term'</a> below.)</p><p class="headingAnchor" id="H3977472528"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects such as psychotomimetic effects may occur more often with <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> than <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> [<a href="#rid1">1</a>]. However, no head-to-head trials comparing the two drugs have been published.</p><p>One review of adverse effects in patients treated for resistant depression with <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> found that side effects occur more often with ketamine than placebo or active controls [<a href="#rid12">12</a>]. However, most side effects resolved spontaneously.</p><p class="headingAnchor" id="H1300874130"><span class="h3">Short term</span><span class="headingEndMark"> — </span>Short-term <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for treatment-resistant depression is generally safe and well tolerated [<a href="#rid6">6,29,35,62</a>]. In a pooled analysis of three randomized trials, which called for either a single infusion of intravenous ketamine 0.5 mg/kg over 40 minutes or multiple infusions over a 12-day period, 97 patients received a total of 205 infusions [<a href="#rid35">35</a>]. During the 205 infusions, early discontinuation due to adverse effects (hypertension, anxiety, or hypotension) occurred in 2 percent.</p><p>For patients with treatment-resistant depression who receive intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, side effects peak within two hours [<a href="#rid3">3</a>]. In short-term studies (eg, ≤30 days), transient adverse effects included:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dissociation and psychotomimetic effects</strong> – A review of 60 studies (randomized trials and observational studies with nearly 900 patients) found that dissociation and psychotomimetic effects were reported in more than 70 percent of the studies [<a href="#rid12">12</a>]. Studies of intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> were two times more likely to report dissociation and psychotomimetic effects than nonintravenous studies.</p><p></p><p class="bulletIndent1">Randomized trials, which typically administered a single intravenous dose of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, indicate that ketamine causes significant, clinically large dissociative and psychotomimetic effects at 40 to 60 minutes after initiating infusion, which subsequently resolved within four hours [<a href="#rid4">4,6,36,38,40,45</a>]. In one trial that administered repeated infusions for up to four weeks, the intensity of dissociative symptoms appeared to diminish with repeated infusions [<a href="#rid36">36</a>]. Results from another trial suggest that dissociation occurs in a dose response manner. (See <a class="local">'Intravenous'</a> above.)</p><p></p><p class="bulletIndent1">Multiple randomized trials studying <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for treatment-resistant depression have excluded patients with psychotic features [<a href="#rid16">16,25,28,34-36,40,65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular</strong> – A review of 60 studies (randomized trials and observational studies) found that nearly 40 percent of the studies described cardiovascular changes [<a href="#rid12">12</a>]. In randomized trials, which typically administered a single intravenous dose of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, hemodynamic effects included time-limited increases in blood pressure and heart rate:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systolic blood pressure – In four randomized trials, mean increases in systolic blood pressure ranged from 8 to 19 mmHg within 40 minutes of infusion, which normalized in four hours or less [<a href="#rid4">4,16,40</a>]. In a pooled analysis of three randomized trials that included 97 patients who received a total of 205 infusions, the transient average peak increase was 20 mmHg [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diastolic blood pressure – In a pooled analysis of three randomized trials that included 97 patients who received a total of 205 infusions, the transient average peak increase in diastolic blood pressure was 13 mmHg [<a href="#rid35">35</a>]. Two subsequent randomized trials found that mean increases ranged from 8 to 13 mmHg within 40 minutes of infusion, which normalized in two hours or less [<a href="#rid16">16,40</a>].</p><p></p><p class="bulletIndent2">In addition, a retrospective study included 66 patients with a mean age of 57 years who received an average of 10 <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> infusions, 0.5 mg/kg over 40 minutes [<a href="#rid66">66</a>]. Essential hypertension controlled by pharmacotherapy was present in 36 percent. An increase in systolic pressure &gt;30 mmHg or in diastolic pressure &gt;15 mmHg during at least one infusion occurred in 50 percent of the patients. Nearly 80 percent of the blood pressure elevations occurred 30 to 40 minutes after onset of the infusion, and all of the elevated readings resolved within 70 minutes of onset.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulse – In one randomized trial, the mean heart rate increased by nine beats/minute within two hours of infusion, which subsequently normalized [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">Results from randomized trials suggest that elevated blood pressure and pulse occur at higher doses in a dose response manner. (See <a class="local">'Intravenous'</a> above.)</p><p></p><p class="bulletIndent1">Other cardiovascular changes that may occur include chest pain, palpitations, and/or pressure, which generally resolved within 90 minutes of receiving <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other common, transient adverse effects of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> in randomized trials included [<a href="#rid36">36,40,53</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anxiety</p><p class="bulletIndent2"><span class="glyph">•</span>Blurred vision</p><p class="bulletIndent2"><span class="glyph">•</span>Dizziness</p><p class="bulletIndent2"><span class="glyph">•</span>Headache</p><p class="bulletIndent2"><span class="glyph">•</span>Nausea or vomiting</p><p></p><p>The transient adverse effects of intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> in patients with treatment-resistant depression occurred at subanesthetic doses. The adverse effects of intravenous ketamine when used to induce general anesthesia  (<a class="graphic graphic_table graphicRef102350" href="/z/d/graphic/102350.html" rel="external">table 1</a>) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Disadvantages and adverse effects'</a>.)</p><p class="headingAnchor" id="H319315362"><span class="h3">Longer term</span><span class="headingEndMark"> — </span>Longer-term, repeated use of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> can lead to:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abuse and addiction</strong> – <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> can act as a transient intoxicant/euphoriant/hallucinogenic and is liable to abuse, addiction, and diversion as an illicit recreational drug (street name “Special K”) [<a href="#rid6">6,8</a>]. Thus, multiple randomized trials studying ketamine for treatment-resistant depression have excluded patients with substance related and addictive disorders [<a href="#rid16">16,25,35,36,40,65</a>]. One case report described a patient with treatment-resistant major depression who received intranasal ketamine for self-administration at home and developed ketamine use disorder [<a href="#rid11">11</a>]. Another case report described ketamine use disorder in a nurse who stole intramuscular ketamine from her hospital for self-medication of major depression that had never been treated with antidepressants [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1">The abuse potential of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> may be related to its structural similarity to phencyclidine and its agonist activity at opioid receptors [<a href="#rid2">2,6,11,12</a>]. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurotoxicity</strong> – Studies in <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> abusers and rodents have found adverse effects on brain structure and function, including cognitive function [<a href="#rid4">4,6,12,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bladder toxicity</strong> – <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> abuse is associated with bladder dysfunction that may require surgery [<a href="#rid8">8,12,68,69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatoxicity</strong> – <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> abuse is associated with liver injury [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H3843792352"><span class="h1">ESKETAMINE</span></p><p class="headingAnchor" id="H859625906"><span class="h2">Administration</span><span class="headingEndMark"> — </span>Information about administering intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> is available through the prescribing information approved by the United States [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H2217923545"><span class="h3">Setting</span><span class="headingEndMark"> — </span>In the United States, intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> is available only through a Risk Evaluation and Mitigation Strategy program, in which the drug is sold to certified medical offices for specific patients who are enrolled in a registry [<a href="#rid71">71</a>]. Patients self-administer the drug in the office and are then monitored for at least two hours by clinicians in the office. Esketamine is kept under lock and key and is not allowed to leave the office. This program is intended to ensure safety and prevent misuse and diversion.</p><p class="headingAnchor" id="H2588564519"><span class="h3">Route (formulation)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">Esketamine</a> is generally administered as a nasal spray.</p><p class="headingAnchor" id="H2842193453"><span class="h3">Dose</span><span class="headingEndMark"> — </span>The dose of intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> for treatment-resistant depression on day 1 of treatment is 56 mg [<a href="#rid70">70</a>]. Subsequent doses are 56 mg or 84 mg, depending upon efficacy and tolerability.</p><p>For acute suicidal ideation or behavior in adults with unipolar major depression, the dose of <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> is 84 mg [<a href="#rid72">72</a>]. The dose may be reduced to 56 mg, based upon tolerability.</p><p><a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">Esketamine</a> may be more potent than <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> in treating major depression. In one randomized trial, intravenous esketamine 0.2 mg/kg was superior to placebo [<a href="#rid17">17</a>]. By contrast, two other randomized trials found that the benefit of intravenous ketamine 0.2 mg/kg and placebo was comparable [<a href="#rid16">16,34</a>].</p><p class="headingAnchor" id="H1228961948"><span class="h3">Frequency</span><span class="headingEndMark"> — </span>The recommended frequency of intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> for treatment-resistant depression is as follows [<a href="#rid70">70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weeks 1 through 4 – Two times/week</p><p class="bulletIndent1"><span class="glyph">●</span>Weeks 5 through 8 – Once/week</p><p class="bulletIndent1"><span class="glyph">●</span>Thereafter – Once every one to two weeks</p><p></p><p>The recommended frequency of intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> for acute suicidal ideation or behavior in adults with unipolar major depression is twice weekly for four weeks [<a href="#rid72">72</a>]. After four weeks of treatment with esketamine, its benefit should be evaluated to determine the need for ongoing treatment.</p><p class="headingAnchor" id="H1611160403"><span class="h2">Concurrent treatment</span><span class="headingEndMark"> — </span>For treatment-resistant depression, <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> has been administered both as monotherapy and as add-on therapy with antidepressants [<a href="#rid17">17,73,74</a>]. For treatment of suicidal ideation in patients with unipolar major depression, esketamine is combined with an antidepressant.</p><p class="headingAnchor" id="H3497360370"><span class="h2">Efficacy</span></p><p class="headingAnchor" id="H1270051787"><span class="h3">Short term</span><span class="headingEndMark"> — </span>For unipolar major depression, the efficacy of <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> and <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> appear to be comparable [<a href="#rid1">1</a>]. However, no head-to-head trials comparing the two drugs have been published.</p><p>Based upon short-term randomized trials, a single dose of intravenous or intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> can ameliorate treatment-resistant depression, including symptoms of suicidality requiring hospitalization, within two to four hours. In addition, response (reduction of baseline symptoms &gt;50 percent) during short-term trials occurs in approximately 25 to 65 percent of patients with unipolar major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>One trial assigned 30 patients to receive intravenous infusions of <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> 0.2 mg/kg, esketamine 0.4 mg/kg, or placebo [<a href="#rid17">17</a>]. Double-blind treatment occurred during the first week, with infusions on day 1 and day 4, followed by open-label treatment with up to four infusions of esketamine over two weeks, and a subsequent follow-up assessment-only phase for another two weeks. Following the first dose of study drug, improvement with each dose of esketamine occurred within two hours, and response at 24 hours after the infusion occurred in more patients treated with esketamine 0.2 mg/kg or esketamine 0.4 mg/kg than placebo (67 and 64 versus 0 percent). The benefit of active treatment persisted for the entire five weeks of the study. The most common adverse effects of esketamine were dissociation, headache, and nausea; in two cases, esketamine 0.4 mg/kg caused severe dissociation that resolved within four hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent one-week trial assigned 67 patients treated with antidepressants to add-on intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> 28 mg, esketamine 56 mg, esketamine 84 mg, or placebo twice weekly [<a href="#rid73">73</a>]. Exclusion criteria included history of substance use disorder and psychotic disorder. Improvement of depression was greater with each dose of esketamine than placebo, the antidepressant effect began within two hours of the first dose, and larger doses of esketamine provided a greater benefit than smaller doses. Response with esketamine 28 mg, 56 mg, 84 mg, and placebo occurred in 36, 27, 42, and 3 percent of patients. The benefit of active treatment persisted during subsequent open-label treatment (total treatment = 74 days) once per week, as well as eight weeks of post-treatment follow-up. The most common adverse effects of esketamine were dizziness, headache, dissociation, and nausea. In addition, most patients treated with esketamine experienced elevations in systolic/diastolic blood pressure within 40 minutes of administering the drug, with a maximum mean change of 19/10 mm Hg. The elevated values typically returned to baseline within two hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A four-week trial compared twice weekly intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> with placebo in 66 patients with unipolar major depression who were initially hospitalized for approximately five days due to imminent risk of suicide [<a href="#rid74">74</a>]. Inclusion criteria did not specify treatment-resistant depression. Exclusion criteria included current substance use disorder and history of psychotic disorder. All patients received standard antidepressants and 24 percent received augmentation pharmacotherapy. The dose of esketamine was 84 or 56 mg, depending upon tolerability.</p><p></p><p class="bulletIndent1">Improvement of depression was greater with <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> than placebo at 4 hours, 24 hours, and 48 hours after the initial dose, and the clinical effects were moderate to large. In addition, remission at day 25 with esketamine and placebo occurred in 60 and 42 percent of patients; although a statistical test was not reported, a difference of this magnitude, if real, would be clinically meaningful. The number needed to treat was six, meaning that one additional remission occurred with esketamine for every six patients treated with esketamine and every six treated with placebo.</p><p></p><p class="bulletIndent1">Discontinuation of treatment due to adverse effects occurred nearly five times more often with active drug than placebo (14 and 3 percent of patients [5/35 and 1/31]). Adverse effects that occurred in at least twice as many patients who received <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> than placebo included anxiety, dissociation, dizziness, nausea, vomiting, paresthesia, and sedation. Dissociation resolved within two hours of onset and was less severe with repeated doses. In addition, elevations in blood pressure occurred each day that study drugs were administered and generally resolved within two hours; the maximum mean increases of systolic/diastolic pressures with esketamine and placebo were 17/12 and 9/8 mmHg.</p><p></p><p class="headingAnchor" id="H1134760771"><span class="h3">Longer term</span><span class="headingEndMark"> — </span>Among patients with acute major depression who are successfully treated with <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> plus an antidepressant, maintenance treatment with the combination is more efficacious than antidepressant monotherapy. In one study, patients acutely ill with treatment-resistant, unipolar major depression received open-label oral antidepressant plus intranasal esketamine [<a href="#rid75">75</a>]. Patients who either remitted or responded (reduction of baseline symptoms ≥50 percent without achieving remission) were randomly assigned to maintenance treatment with the antidepressant plus either esketamine (56 or 84 mg) or placebo. Maintenance treatment lasted for approximately 80 weeks, during which adjunctive esketamine or placebo were administered once every week or every other week. Among patients who:</p><p class="bulletIndent1"><span class="glyph">●</span>Remitted (n = 176), relapse occurred in fewer patients who received the combination than antidepressant monotherapy (27 versus 45 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Responded without remission (n = 121), relapse occurred in fewer patients who received the combination than antidepressant monotherapy (26 versus 58 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Remitted or responded (n = 297), the most common adverse effects that occurred with adjunctive <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> were dysgeusia, vertigo, dissociation, somnolence, and dizziness; the incidence of each adverse effect ranged from 20 to 27 percent. By contrast, the incidence of each adverse effect with placebo was &lt;7 percent.</p><p></p><p class="headingAnchor" id="H4266624301"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects such as psychotomimetic effects may occur less often with <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> than <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> [<a href="#rid1">1</a>]. However, no head-to-head trials comparing the two drugs have been published.</p><p>Randomized trials compared intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> plus antidepressant with placebo plus antidepressant in a total of 568 patients with treatment-resistant depression [<a href="#rid70">70</a>]. The frequency of adverse effects with adjunctive esketamine versus placebo included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety – 13 versus 6 percent of patients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased blood pressure – 10 versus 3 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dissociation – 41 versus 9 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness – 29 versus 8 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoesthesia – 18 versus 2 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lethargy (fatigue) – 11 versus 5 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nausea – 28 versus 9 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vomiting – 9 versus 2 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sedation (somnolence) – 23 versus 9 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vertigo – 23 versus 3 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Feeling drunk – 5 versus 1 percent</p><p></p><p>We presume that longer term, repeated use of <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> can potentially lead to adverse effects that are seen with longer-term, repeated use of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>. (See <a class="local">'Longer term'</a> above.)</p><p class="headingAnchor" id="H3689550236"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H1926072115"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemical structure</strong> – <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> is a racemic mixture of two enantiomers, S-ketamine (<a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a>) and R-ketamine. (See <a class="local">'Introduction'</a> above and <a class="local">'Chemical structure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indication</strong> – <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> or <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> may be indicated for treatment-resistant, severe unipolar major depression without psychotic features, if patients have failed or declined other indicated treatments. Patients receiving ketamine or esketamine should be under the care of a psychiatrist who can determine whether other treatments have been appropriately administered and can monitor the outcome of the ketamine/esketamine trial. (See  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Although the mechanism of action for the rapid antidepressant effects of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> or <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> is not known, several studies indicate that ketamine has an affinity for multiple receptors. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – If <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> is used for treatment-resistant depression, clinicians need to determine different aspects of administration, including setting, route of administration, dose, frequency, and use of concomitant medications. (See <a class="local">'Administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Randomized trials have demonstrated that intravenous <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> and intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> can each rapidly improve treatment-resistant depression. (See <a class="local">'Short-term efficacy'</a> above and <a class="local">'Short term'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ketamine</strong> – In patients treated for resistant depression with <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, side effects occur more often with ketamine than placebo or active controls. Short-term adverse effects include dissociation, psychotomimetic effects, and cardiovascular changes such as increased systolic and diastolic blood pressure and increased pulse; most of these side effects resolve quickly. However, ketamine can act as a transient intoxicant and is liable to abuse, addiction, and diversion as an illicit recreational drug. Ketamine abuse is also associated with neurotoxicity and bladder dysfunction. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Esketamine</strong> – Adverse effects that occur at least twice as often with intranasal <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">esketamine</a> plus antidepressant, compared with placebo plus antidepressant, include anxiety, increased blood pressure, dissociation, dizziness, nausea, sedation, and vertigo. We presume that longer-term, repeated use of esketamine can potentially lead to adverse effects that are seen with longer-term, repeated use of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>. (See <a class="local">'Adverse effects'</a> above and <a class="local">'Longer term'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Andrade C. Ketamine for Depression, 3: Does Chirality Matter? J Clin Psychiatry 2017; 78:e674.</a></li><li class="breakAll">Mathai DS, Mathew SJ. Ketamine. In: The American Psychiatric Association Publishing Textbook of Psychiatry, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.549.</li><li><a class="nounderline abstract_t">Andrade C. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. J Clin Psychiatry 2017; 78:e415.</a></li><li><a class="nounderline abstract_t">Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry 2015; 172:950.</a></li><li><a class="nounderline abstract_t">Nemeroff CB. Ketamine: Quo Vadis? Am J Psychiatry 2018; 175:297.</a></li><li><a class="nounderline abstract_t">Malhi GS, Byrow Y, Cassidy F, et al. Ketamine: stimulating antidepressant treatment? BJPsych Open 2016; 2:e5.</a></li><li><a class="nounderline abstract_t">Wilkinson ST, Toprak M, Turner MS, et al. A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. Am J Psychiatry 2017; 174:695.</a></li><li><a class="nounderline abstract_t">Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017; 74:399.</a></li><li><a class="nounderline abstract_t">Freedman R, Brown AS, Cannon TD, et al. Can a Framework Be Established for the Safe Use of Ketamine? Am J Psychiatry 2018; 175:587.</a></li><li><a class="nounderline abstract_t">Williams NR, Schatzberg AF. NMDA antagonist treatment of depression. Curr Opin Neurobiol 2016; 36:112.</a></li><li><a class="nounderline abstract_t">Schak KM, Vande Voort JL, Johnson EK, et al. Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment. Am J Psychiatry 2016; 173:215.</a></li><li><a class="nounderline abstract_t">Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 2018; 5:65.</a></li><li><a class="nounderline abstract_t">Williams NR, Heifets BD, Blasey C, et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. Am J Psychiatry 2018; 175:1205.</a></li><li><a class="nounderline abstract_t">Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov 2017; 16:472.</a></li><li><a class="nounderline abstract_t">Reardon S. Party drug's power to fight depression puzzles scientists​. Nature 2017; 545:17.</a></li><li><a class="nounderline abstract_t">Su TP, Chen MH, Li CT, et al. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Neuropsychopharmacology 2017; 42:2482.</a></li><li><a class="nounderline abstract_t">Singh JB, Fedgchin M, Daly E, et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biol Psychiatry 2016; 80:424.</a></li><li><a class="nounderline abstract_t">Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533:481.</a></li><li><a class="nounderline abstract_t">Chen MH, Li CT, Lin WC, et al. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study. J Affect Disord 2018; 225:709.</a></li><li><a class="nounderline abstract_t">Deyama S, Bang E, Wohleb ES, et al. Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine. Am J Psychiatry 2019; 176:388.</a></li><li><a class="nounderline abstract_t">Yang Y, Cui Y, Sang K, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature 2018; 554:317.</a></li><li><a class="nounderline abstract_t">Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry 2012; 72:537.</a></li><li><a class="nounderline abstract_t">Mathews DC, Zarate CA Jr. Current status of ketamine and related compounds for depression. J Clin Psychiatry 2013; 74:516.</a></li><li><a class="nounderline abstract_t">Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170:1134.</a></li><li><a class="nounderline abstract_t">Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry 2019; 214:20.</a></li><li><a class="nounderline abstract_t">Loo C. Can we confidently use ketamine as a clinical treatment for depression? Lancet Psychiatry 2018; 5:11.</a></li><li><a class="nounderline abstract_t">Gálvez V, O'Keefe E, Cotiga L, et al. Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report. Biol Psychiatry 2014; 76:e1.</a></li><li><a class="nounderline abstract_t">Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014; 76:970.</a></li><li><a class="nounderline abstract_t">Andrade C. Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? J Clin Psychiatry 2017; 78:e852.</a></li><li><a class="nounderline abstract_t">Gálvez V, Li A, Huggins C, et al. Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol 2018; 32:397.</a></li><li><a class="nounderline abstract_t">Quintana DS, Steen NE, Andreassen OA. The Promise of Intranasal Esketamine as a Novel and Effective Antidepressant. JAMA Psychiatry 2018; 75:123.</a></li><li><a class="nounderline abstract_t">Daly EJ, Singh JB. Adjunctive Intranasal Esketamine in Treatment-Resistant Depression-Reply. JAMA Psychiatry 2018; 75:654.</a></li><li><a class="nounderline abstract_t">Chilukuri H, Reddy NP, Pathapati RM, et al. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med 2014; 36:71.</a></li><li><a class="nounderline abstract_t">Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 2020; 25:1592.</a></li><li><a class="nounderline abstract_t">Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry 2015; 76:247.</a></li><li><a class="nounderline abstract_t">Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry 2016; 173:816.</a></li><li><a class="nounderline abstract_t">Andrade C. Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions. J Clin Psychiatry 2017; 78:e858.</a></li><li><a class="nounderline abstract_t">Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 2016; 46:1459.</a></li><li><a class="nounderline abstract_t">Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry 2018; 175:150.</a></li><li><a class="nounderline abstract_t">Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry 2018; 175:327.</a></li><li><a class="nounderline abstract_t">Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol 2015; 35:334.</a></li><li><a class="nounderline abstract_t">Albott CS, Shiroma PR, Cullen KR, et al. The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use. J Clin Psychiatry 2017; 78:e308.</a></li><li><a class="nounderline abstract_t">Andrade C. Ketamine for Depression, 2: Diagnostic and Contextual Indications. J Clin Psychiatry 2017; 78:e555.</a></li><li><a class="nounderline abstract_t">Wilkinson ST, Wright D, Fasula MK, et al. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychother Psychosom 2017; 86:162.</a></li><li><a class="nounderline abstract_t">Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014; 231:3663.</a></li><li><a class="nounderline abstract_t">McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015; 45:693.</a></li><li><a class="nounderline abstract_t">Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015; :CD011612.</a></li><li><a class="nounderline abstract_t">Xu Y, Hackett M, Carter G, et al. Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol 2016; 19.</a></li><li><a class="nounderline abstract_t">Han Y, Chen J, Zou D, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat 2016; 12:2859.</a></li><li><a class="nounderline abstract_t">Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 2015; 30:139.</a></li><li><a class="nounderline abstract_t">Pennybaker SJ, Niciu MJ, Luckenbaugh DA, Zarate CA. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. J Affect Disord 2017; 208:560.</a></li><li><a class="nounderline abstract_t">Rong C, Park C, Rosenblat JD, et al. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. Int J Environ Res Public Health 2018; 15.</a></li><li><a class="nounderline abstract_t">Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Ment Health 2016; 19:35.</a></li><li><a class="nounderline abstract_t">Hu YD, Xiang YT, Fang JX, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 2016; 46:623.</a></li><li><a class="nounderline abstract_t">Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:1155.</a></li><li><a class="nounderline abstract_t">Vande Voort JL, Morgan RJ, Kung S, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord 2016; 206:300.</a></li><li><a class="nounderline abstract_t">Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014; 215:355.</a></li><li><a class="nounderline abstract_t">Thomas RK, Baker G, Lind J, Dursun S. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. J Psychopharmacol 2018; 32:1110.</a></li><li><a class="nounderline abstract_t">Papadimitropoulou K, Vossen C, Karabis A, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin 2017; 33:701.</a></li><li><a class="nounderline abstract_t">Schatzberg AF. A word to the wise about ketamine. Am J Psychiatry 2014; 171:262.</a></li><li><a class="nounderline abstract_t">Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord 2013; 147:416.</a></li><li><a class="nounderline abstract_t">Wilkinson ST, Katz RB, Toprak M, et al. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. J Clin Psychiatry 2018; 79.</a></li><li><a class="nounderline abstract_t">Ryan CJ, Loo C. The practicalities and ethics of ketamine for depression. Lancet Psychiatry 2017; 4:354.</a></li><li><a class="nounderline abstract_t">George MS. Is There Really Nothing New Under the Sun? Is Low-Dose Ketamine a Fast-Acting Antidepressant Simply Because It Is An Opioid? Am J Psychiatry 2018; 175:1157.</a></li><li><a class="nounderline abstract_t">Ballard ED, Yarrington JS, Farmer CA, et al. Characterizing the course of suicidal ideation response to ketamine. J Affect Disord 2018; 241:86.</a></li><li><a class="nounderline abstract_t">Riva-Posse P, Reiff CM, Edwards JA, et al. Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions. J Affect Disord 2018; 236:291.</a></li><li><a class="nounderline abstract_t">Bonnet U. Long-Term Ketamine Self-Injections in Major Depressive Disorder: Focus on Tolerance in Ketamine's Antidepressant Response and the Development of Ketamine Addiction. J Psychoactive Drugs 2015; 47:276.</a></li><li><a class="nounderline abstract_t">Baker SC, Shabir S, Georgopoulos NT, Southgate J. Ketamine-Induced Apoptosis in Normal Human Urothelial Cells: A Direct, N-Methyl-d-Aspartate Receptor-Independent Pathway Characterized by Mitochondrial Stress. Am J Pathol 2016; 186:1267.</a></li><li><a class="nounderline abstract_t">Jhang JF, Birder LA, Chancellor MB, Kuo HC. Patient characteristics for different therapeutic strategies in the management ketamine cystitis. Neurourol Urodyn 2017; 36:687.</a></li><li class="breakAll">United States Food and Drug Administration approved labelling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf (Accessed on March 20, 2019).</li><li class="breakAll">https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified (Accessed on May 13, 2019).</li><li class="breakAll">United States Food and Drug Administration approved labelling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf (Accessed on August 10, 2020).</li><li><a class="nounderline abstract_t">Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2018; 75:139.</a></li><li><a class="nounderline abstract_t">Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry 2018; 175:620.</a></li><li><a class="nounderline abstract_t">Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019; 76:893.</a></li></ol></div><div id="topicVersionRevision">Topic 119992 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28682536" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ketamine for Depression, 3: Does Chirality Matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28682536" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ketamine for Depression, 3: Does Chirality Matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448702" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26423481" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29606064" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ketamine: Quo Vadis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27703782" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ketamine: stimulating antidepressant treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669202" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28249076" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29656666" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Can a Framework Be Established for the Safe Use of Ketamine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26687375" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : NMDA antagonist treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26926127" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28757132" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Side-effects associated with ketamine use in depression: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153752" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28303025" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Targeting glutamate signalling in depression: progress and prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28470222" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Party drug's power to fight depression puzzles scientists​.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492279" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26707087" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144355" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : NMDAR inhibition-independent antidepressant actions of ketamine metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28922734" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30606046" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29446381" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22705040" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ketamine for depression: where do we go from here?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759454" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Current status of ketamine and related compounds for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23982301" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246667" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29277196" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Can we confidently use ketamine as a clinical treatment for depression?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24507509" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24821196" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized controlled trial of intranasal ketamine in major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28749092" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29542371" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282452" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The Promise of Intranasal Esketamine as a Novel and Effective Antidepressant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800990" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adjunctive Intranasal Esketamine in Treatment-Resistant Depression-Reply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24701015" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acute antidepressant effects of intramuscular versus intravenous ketamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30283029" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25271445" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ketamine safety and tolerability in clinical trials for treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056608" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28858450" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26867988" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28969441" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29202655" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25928701" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28394513" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28570803" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ketamine for Depression, 2: Diagnostic and Contextual Indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28490030" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038867" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ketamine administration in depressive disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25010396" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26395901" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ketamine and other glutamate receptor modulators for depression in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26578082" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27843321" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25562451" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27839782" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29673146" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27053196" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ketamine for treatment-resistant depression: recent developments and clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26478208" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21466832" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27656788" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Continuation phase intravenous ketamine in adults with treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24374115" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30182797" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28035869" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585328" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A word to the wise about ketamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182590" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30063304" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28395987" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The practicalities and ethics of ketamine for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153751" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Is There Really Nothing New Under the Sun? Is Low-Dose Ketamine a Fast-Acting Antidepressant Simply Because It Is An Opioid?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30099268" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Characterizing the course of suicidal ideation response to ketamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29525051" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26317449" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-Term Ketamine Self-Injections in Major Depressive Disorder: Focus on Tolerance in Ketamine's Antidepressant Response and the Development of Ketamine Addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001627" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ketamine-Induced Apoptosis in Normal Human Urothelial Cells: A Direct, N-Methyl-d-Aspartate Receptor-Independent Pathway Characterized by Mitochondrial Stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26998599" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Patient characteristics for different therapeutic strategies in the management ketamine cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26998599" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Patient characteristics for different therapeutic strategies in the management ketamine cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26998599" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Patient characteristics for different therapeutic strategies in the management ketamine cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26998599" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Patient characteristics for different therapeutic strategies in the management ketamine cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282469" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29656663" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31166571" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
